HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 142, Issue 9, Pages 1926-1937
Publisher
Wiley
Online
2017-12-06
DOI
10.1002/ijc.31199
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting histone deacetylase to overcome resistance of B-RAFV600E melanoma cells to apoptosis.
- (2017) P. Hersey JOURNAL OF CLINICAL ONCOLOGY
- Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy
- (2016) Michael P. Smith et al. CANCER CELL
- How do tumor cells respond to HDAC inhibition?
- (2016) Andrea Newbold et al. FEBS Journal
- C-myc overexpression drives melanoma metastasis by promoting vasculogenic mimicry via c-myc/snail/Bax signaling
- (2016) Xian Lin et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
- (2015) Willy Hugo et al. CELL
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas
- (2015) Jinhua Wang et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification
- (2015) Matteo Dugo et al. Oncotarget
- Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity
- (2015) Kyung H. Yi et al. Oncotarget
- Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling
- (2015) Anja Heinemann et al. Oncotarget
- Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
- (2015) Zeynep Eroglu et al. Therapeutic Advances in Medical Oncology
- Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032
- (2015) Elisabetta Vergani et al. NEOPLASIA
- The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition
- (2014) Matthew M. K. Chan et al. CANCER
- BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
- (2014) H. Rizos et al. CLINICAL CANCER RESEARCH
- The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells
- (2014) Stuart J. Gallagher et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib
- (2014) Matthias Wirth et al. NUCLEIC ACIDS RESEARCH
- Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAFV600E inhibition and can be targeted to reduce resistance
- (2014) M N Serasinghe et al. ONCOGENE
- Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy
- (2014) Nethia Mohana-Kumaran et al. Pigment Cell & Melanoma Research
- Loss of PI(4,5)P2 5-Phosphatase A Contributes to Resistance of Human Melanoma Cells to RAF/MEK Inhibitors
- (2014) Yan Ye et al. Translational Oncology
- Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
- (2014) Georgina V. Long et al. Nature Communications
- Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
- (2014) Judith Müller et al. Nature Communications
- A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
- (2014) D. J. Konieczkowski et al. Cancer Discovery
- Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
- (2013) Ethan V. Abel et al. JOURNAL OF CLINICAL INVESTIGATION
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
- (2013) Kerstin Trunzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma
- (2013) M. S. Carlino et al. MOLECULAR CANCER THERAPEUTICS
- A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
- (2013) Cory M. Johannessen et al. NATURE
- BCL2A1is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition
- (2013) Rizwan Haq et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3
- (2013) F Lai et al. Cell Death & Disease
- A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
- (2013) H. Shi et al. Cancer Discovery
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance
- (2012) D. Wroblewski et al. CARCINOGENESIS
- All Things to All People
- (2012) Trevor D. Littlewood et al. CELL
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
- (2012) James S. Duncan et al. CELL
- BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance
- (2012) A. M. Alcala et al. CLINICAL CANCER RESEARCH
- SHOC2 and CRAF Mediate ERK1/2 Reactivation in Mutant NRAS-mediated Resistance to RAF Inhibitor
- (2012) Fred M. Kaplan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma
- (2012) Vipin Yadav et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition
- (2012) Kavitha Gowrishankar et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors
- (2012) Fritz Lai et al. MELANOMA RESEARCH
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- (2012) Maria R. Girotti et al. Cancer Discovery
- Combinatorial Treatments That Overcome PDGFR -Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition
- (2011) H. Shi et al. CANCER RESEARCH
- PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
- (2011) K. H. T. Paraiso et al. CANCER RESEARCH
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- (2011) Nikhil Wagle et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress
- (2011) L Dong et al. ONCOGENE
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF- Pathway Signaling Indicates Response to Primary Chemotherapy
- (2010) M. S. Carey et al. CLINICAL CANCER RESEARCH
- MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720
- (2010) C. C. Jiang et al. CLINICAL CANCER RESEARCH
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS
- (2010) C C Jiang et al. Cell Death & Disease
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- (2008) C. Montagut et al. CANCER RESEARCH
- Tumour cell survival signalling by the ERK1/2 pathway
- (2008) K Balmanno et al. CELL DEATH AND DIFFERENTIATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now